Assessment of S100B and CXCL9 as markers of ?activity in non-segmental vitiligo.?

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201810545064445

Enrollment

Registered

2018-10-15

Start date

2018-10-07

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

oral dexamethasone minipulse steroid will be given and skin and blood samples will be collected

skin and blood sample will be collected

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?-? Patients with non-segmental vitiligo.? ?-? Age above 18 years.?

Exclusion criteria

Exclusion criteria: ?-? Patients with segmental vitiligo.? ?-? Patients who received treatment in the past 3 months. ? ?-? Patients with absolute contraindications for systemic steroid therapy.? ?-? Patients with active neurological disease.?

Design outcomes

Primary

Measure	Time frame
Verifying the relation between S100B, CXCL9 and vitiligo activity in patients with ?non-segmental vitiligo and their possible use as diagnostic and prognostic markers ?of disease activity.?	—

Secondary

Measure	Time frame
• Detection the effect of steroid minipulse therapy on S100B and CXCL9 ?levels in active non-segmental vitiligo.? • Detection of a possible relation between the change in S100B and CXCL9 ?levels and subsidence of vitiligo activity.?	—

Countries

Egypt

Contacts

Public Contactkholoud helmy

assisstant lecturer of dermatology faculty of medicine cairo university

kholoudhelmy88@ggmail.com0201223488773

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026